SCHEMBL199471

SCHEMBL199471

CCOC(=O)c1c[nH]n(-c2ccccc2)c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 1.00
ALDH1A1 P00352 8/20 0.80
GAA P10253 4/20 0.52
TSHR P16473 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
KDM4E B2RXH2 4/20 0.49
HPGD P15428 3/20 0.49
GLA P06280 1/20 0.49
POLB P06746 1/20 0.48
HSD17B10 Q99714 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
DPP4 P27487 1/20 0.46
DDAH1 O94760 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5601992 0.86 ALDH1A1 (0.80) MAPTALDH1A1L3MBTL1KDM4ESMN1; SMN2
SCHEMBL5599513 0.86 ALDH1A1 (0.80) MAPTALDH1A1TSHRKDM4EHPGD
SCHEMBL1260172 0.86 ALDH1A1 (0.80) MAPTALDH1A1TSHRL3MBTL1KDM4E
SCHEMBL1259728 0.83 MAPT (0.71) MAPTALDH1A1GAATSHRKDM4E
SCHEMBL1260514 0.81 MAPT (0.68) MAPTALDH1A1GAATSHRKDM4E
SCHEMBL1260421 0.80 MAPT (0.67) MAPTALDH1A1GAATSHRKDM4E
SCHEMBL1258132 0.80 MAPT (0.66) MAPTALDH1A1GAATSHRKDM4E
SCHEMBL10999890 0.78 MAPT (0.63) MAPTALDH1A1GAATSHRKDM4E
SCHEMBL11005506 0.78 MAPT (0.64) MAPTALDH1A1TSHRKDM4EHPGD
SCHEMBL19377624 0.78 MAPT (0.64) MAPTALDH1A1GAATSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851064-B2 ACSS2 inhibitors and methods of use thereof METABOMED LTD. (IL) 2020-12-01 US disclosed
US-20190263758-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2019-08-29 US disclosed
EP-1881976-B1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC (US) 2012-10-17 EP disclosed
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 US disclosed
US-8088794-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2012-01-03 US disclosed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed
US-20080269293-A1 PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS PFIZER INC. 2008-10-30 US disclosed
US-20080269293-A1 PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS PFIZER INC. 2008-10-30 US disclosed
WO-2008023235-A1 PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS PFIZER PRODUCTS INC. (US) 2008-02-28 WO disclosed
EP-1881976-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS Amgen Inc., (US) 2008-01-30 EP disclosed
WO-2006116713-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC. (US) 2006-11-02 WO disclosed
US-4537886-A β-lactam antibacterial agents and compositions containing them BEECHAM GROUP P.L.C. (GB) 1985-08-27 US disclosed
EP-0090656-A1 Penicillins, a process for the preparation and compositions containing them BEECHAM GROUP PLC (GB) 1983-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851064-B2 ACSS2 inhibitors and methods of use thereof ACSS2, GLS2, ADSS2 MAPT 2884/4885ALDH1A1 238/4885GAA 1153/4885
US-20080269293-A1 PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS P2RY1, P2RY11, P2RX7 MAPT 4693/4885ALDH1A1 1380/4885GAA 3831/4885
US-20080312232-A1 Substituted amide derivatives and methods of use HGF, HGFAC, MET MAPT 3239/4885ALDH1A1 76/4885GAA 54/4885
US-20190263758-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ADSS2 MAPT 2884/4885ALDH1A1 238/4885GAA 1153/4885
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES HGF, HGFAC, MET MAPT 3482/4885ALDH1A1 58/4885GAA 78/4885
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET MAPT 3239/4885ALDH1A1 76/4885GAA 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.